Nanosuspension-Based Dissolvable Microneedle Arrays to Enhance Diclofenac Skin Delivery.
diclofenac
dissolving microneedles
nanocrystals
nanosuspension
skin delivery
transdermal delivery
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Sep 2023
13 Sep 2023
Historique:
received:
14
08
2023
revised:
30
08
2023
accepted:
07
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Applying a formulation on the skin represents a patient-acceptable and therapeutically effective way to administer drugs locally and systemically. However, the stratum corneum stands as an impermeable barrier that only allows a very limited number of drugs to be distributed in the underlying tissues, limiting the feasibility of this administration route. Microneedle arrays are minimally invasive platforms that allow the delivery of drugs within/across the skin through the temporary mechanical disruption of the stratum corneum. In this work, microneedle arrays were combined with nanosuspensions, a technology for solubility enhancement of water insoluble molecules, for the skin delivery of diclofenac. Nanosuspensions were prepared using a top-down method and loaded in the tips of 500 µm or 800 µm high microneedles. The quality of the combined platform was assessed using electron microscopy and spectroscopic and calorimetry techniques, demonstrating the ability to load high amounts of the hydrophobic drug and the compatibility between excipients. Lastly, the application of nanosuspension-loaded microneedles on the skin in vitro allowed the delivery of diclofenac within and across the stratum corneum, proving the potential of this combination to enhance skin delivery of scarcely soluble drugs.
Identifiants
pubmed: 37765277
pii: pharmaceutics15092308
doi: 10.3390/pharmaceutics15092308
pmc: PMC10536216
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmaceutics. 2019 Jul 02;11(7):
pubmed: 31269648
J Pain Palliat Care Pharmacother. 2017 Jun;31(2):113-120
pubmed: 28388238
J Adv Pharm Technol Res. 2011 Apr;2(2):81-7
pubmed: 22171298
Mol Pharm. 2017 Jun 5;14(6):1998-2009
pubmed: 28409629
J Control Release. 2012 Jul 20;161(2):645-55
pubmed: 22342643
J Control Release. 2022 Aug;348:186-205
pubmed: 35662577
Pharmaceutics. 2021 Jul 31;13(8):
pubmed: 34452149
Pharmaceutics. 2020 Jun 19;12(6):
pubmed: 32575392
J Pain Res. 2015 Feb 20;8:105-18
pubmed: 25759598
J Control Release. 2022 Nov;351:361-380
pubmed: 36169040
J Control Release. 2014 Jul 10;185:130-8
pubmed: 24806483
Pharmaceutics. 2022 Dec 15;14(12):
pubmed: 36559310
Expert Opin Biol Ther. 2002 Oct;2(7):723-33
pubmed: 12387671
ChemMedChem. 2019 Jan 8;14(1):8-23
pubmed: 30457705
Int J Pharm. 2014 Jun 5;467(1-2):27-33
pubmed: 24680963
Pharmaceutics. 2020 Nov 25;12(12):
pubmed: 33255623
Eur J Pharm Sci. 2021 Sep 1;164:105895
pubmed: 34087357
Pharmaceutics. 2022 May 19;14(5):
pubmed: 35631674
J Control Release. 2018 Jan 28;270:184-202
pubmed: 29203415
Curr Opin Pharmacol. 2014 Dec;19:11-6
pubmed: 24929967
J Control Release. 2019 Dec 10;315:97-113
pubmed: 31644938
Res Pharm Sci. 2010 Jan;5(1):49-56
pubmed: 21589768
Eur J Pharm Sci. 2015 Sep 18;77:208-15
pubmed: 26116276
Int J Pharm. 2006 Apr 7;312(1-2):179-86
pubmed: 16469459